PINK1 and Parkinson disease: Unlike intraperitoneal administration, another rationale for intranasal delivery of these nootropic agents is that direct nose-to-brain targeting is a non-invasive therapeutic alternative to achieve high bioavailability of active ingredients (Forskolin and Noopept) in the brain to reverse PD pathology in PINK1-KO rats.